Integrated analysis on the N6 ‐methyladenosine‐related long noncoding RNAs prognostic signature, immune checkpoints, and immune cell infiltration in clear cell renal cell carcinoma

ConclusionsThe seven m6A-related lncRNAs prognostic risk signature showed reliable prognostic predictive power for ccRCC and was associated with the expression of immune checkpoints and immune cell infiltration. This seven m6A-related lncRNAs signature will be helpful in managing ccRCC and guiding individualized immunotherapy.
Source: Immunity, Inflammation and Disease - Category: Allergy & Immunology Authors: Tags: ORIGINAL ARTICLE Source Type: research

Related Links:

Can J Urol. 2021 Oct;28(5):10806-10816.ABSTRACTINTRODUCTION: To investigate the impact of facility type and volume on survival in patients with metastatic renal cell carcinoma (mRCC).MATERIALS AND METHODS: We investigated the National Cancer Database for patients with mRCC. Patients were stratified according to treatment facility type (academic vs. non-academic) and facility volume (high, intermediate, and low). Kaplan-Meier survival estimates and Cox proportional hazard models were fitted to evaluate overall survival (OS) as a function of facility type, volume, and different treatment modalities.RESULTS: A total of 27,598...
Source: Canadian Journal of Urology - Category: Urology & Nephrology Authors: Source Type: research
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a rare autosomal dominant disorder that results from a germline mutation in the fumarate hydratase (FH) gene; it manifests as cutaneous leiomyomas, uterine fibroids, and renal cell cancer (RCC). Patients with HLRCC-associated RCC (HLRCC-RCC) have aggressive clinical courses, but there is no standardized therapy for advanced HLRCC-RCC. Here, we describe aggressive HLRCC in a 26-year-old man who presented with RCC that exhibited a novel heterozygous germline insertion mutation in exon 2 of the FH gene (c.191dupA: p.N64fs). Systemic lymph node metastasis had already o...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: Overall, significant differences in the diversity and composition of the gut microbiome were identified in ICIs responders and non-responders. Our findings provide new insights into the value of assessing the gut microbiome in immunotherapy. Further robust randomized controlled trials (RCTs) examining the modulatory effects of the gut microbiome and FMT on ICIs in patients not responding to immunotherapy are warranted.PMID:34638308 | DOI:10.3390/cancers13194824
Source: Genomics Proteomics ... - Category: Genetics & Stem Cells Authors: Source Type: research
A novel clinical trial involving the immunotherapy combination of Opdivo and Yervoy will open soon in Chicago. The goal is to study the drugs’ efficacy when added to surgery for patients with peritoneal mesothelioma cancer. The single-center, phase II clinical trial follows a recent report detailing the impressive three-year effectiveness of the drug combination when used for unresectable pleural mesothelioma. Bristol Myers Squibb manufactures Opdivo and Yervoy, known generically as nivolumab and ipilimumab. The U.S. Food and Drug Administration approved the combination for pleural mesothelioma in 2020, making ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
J Pathol Clin Res. 2021 Oct 7. doi: 10.1002/cjp2.241. Online ahead of print.ABSTRACTThe tumor microenvironment (TME), including immune cells, cancer-associated fibroblasts, endothelial cells, adjacent normal cells, and others, plays a crucial role in influencing tumor behavior and progression. Here, we characterized the TME in 83 primary renal tumors and matched metastatic or recurrence tissue samples (n = 15) from papillary renal cell carcinoma (pRCC) types 1 (n = 20) and 2 (n = 49), collecting duct carcinomas (CDC; n = 14), and high-grade urothelial carcinomas (HGUC; n = 5). We investigated 10 different markers of immune...
Source: Cell Research - Category: Cytology Authors: Source Type: research
AbstractRenal cell carcinoma (RCC) is one of the most lethal urological cancers, highly resistant to chemo and radiotherapy. Obesity and smoking are the best-known risk factors of RCC, both related to oxidative stress presence, suggesting a significant role in RCC development and maintenance. Surgical resection is the treatment of choice for localized RCC; however, this neoplasia is hardly diagnosable at its initial stages, occurring commonly in late phases and even when metastasis is already present. Systemic therapies are the option against RCC in these more advanced stages, such as cytokine therapy or a combination of t...
Source: BioFactors - Category: Biochemistry Authors: Tags: Review Article Source Type: research
Conclusions: Overall, significant differences in the diversity and composition of the gut microbiome were identified in ICIs responders and non-responders. Our findings provide new insights into the value of assessing the gut microbiome in immunotherapy. Further robust randomized controlled trials (RCTs) examining the modulatory effects of the gut microbiome and FMT on ICIs in patients not responding to immunotherapy are warranted.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Conclusions: This retrospective study points out that early systemic steroids administration to manage irAEs might not have a detrimental effect on patient clinical outcome in NSCLC, melanoma and RCC patients.
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
This study explored thePBRM1-associated immunological features and identified the immune-related genes (IRGs) linked toPBRM1 mutation using bioinformatics methods. A total of 37 survival IRGs associated withPBRM1 mutation in ccRCC patients were identified. To further explore the role of these IRGs in ccRCC and their association with immune status, eight IRGs with remarkable potential as individual targets were selected. An immune model that was constructed showed good performance in stratifying patients into different subgroups, showing clinical application potential compared to traditional clinical factors. Patients in th...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: RESEARCH ARTICLE Source Type: research
Anti-angiogenic agents and immunotherapy are the cornerstone of advanced/metastatic renal-cell carcinoma (mRCC) treatment. Recently, the therapeutic scenario of first-line therapy for mRCC has been completely revolutionized. The combination of the two immune checkpoint inhibitors (ICIs) nivolumab and ipilimumab (targeting PD-1 and CTLA4, respectively) yielded a significant survival advantage, compared to sunitinib, in International Metastatic RCC Database consortium (IMDC) intermediate- and poor-risk patients, but failed to improve outcomes of favorable-risk patients [1].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Carcinoma | Databases & Libraries | Immunotherapy | Kidney Cancer | Renal Cell Carcinoma